KR101529334B1 - 엔도시알린의 리간드에 대한 결합을 억제하는 방법 - Google Patents

엔도시알린의 리간드에 대한 결합을 억제하는 방법 Download PDF

Info

Publication number
KR101529334B1
KR101529334B1 KR1020097023061A KR20097023061A KR101529334B1 KR 101529334 B1 KR101529334 B1 KR 101529334B1 KR 1020097023061 A KR1020097023061 A KR 1020097023061A KR 20097023061 A KR20097023061 A KR 20097023061A KR 101529334 B1 KR101529334 B1 KR 101529334B1
Authority
KR
South Korea
Prior art keywords
thr
pro
ser
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097023061A
Other languages
English (en)
Korean (ko)
Other versions
KR20100016221A (ko
Inventor
유홍 주
브라이언 이. 톰코윅
루이기 그라소
필립 엠. 사스
니콜라스 씨. 니콜레이디스
Original Assignee
모르포테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포테크, 인크. filed Critical 모르포테크, 인크.
Publication of KR20100016221A publication Critical patent/KR20100016221A/ko
Application granted granted Critical
Publication of KR101529334B1 publication Critical patent/KR101529334B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020097023061A 2007-04-05 2008-04-04 엔도시알린의 리간드에 대한 결합을 억제하는 방법 Active KR101529334B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US60/910,362 2007-04-05
US98002607P 2007-10-15 2007-10-15
US60/980,026 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (2)

Publication Number Publication Date
KR20100016221A KR20100016221A (ko) 2010-02-12
KR101529334B1 true KR101529334B1 (ko) 2015-06-16

Family

ID=39714208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097023061A Active KR101529334B1 (ko) 2007-04-05 2008-04-04 엔도시알린의 리간드에 대한 결합을 억제하는 방법

Country Status (20)

Country Link
US (4) US7807382B2 (OSRAM)
EP (2) EP2137217B1 (OSRAM)
JP (2) JP5825784B2 (OSRAM)
KR (1) KR101529334B1 (OSRAM)
CN (1) CN101918446B (OSRAM)
AU (1) AU2008237296B2 (OSRAM)
BR (1) BRPI0809665B8 (OSRAM)
CA (1) CA2682726C (OSRAM)
CY (2) CY1115370T1 (OSRAM)
DK (2) DK2137217T3 (OSRAM)
ES (2) ES2452929T3 (OSRAM)
HR (2) HRP20140266T1 (OSRAM)
HU (1) HUE031269T2 (OSRAM)
LT (1) LT2620451T (OSRAM)
MX (1) MX2009010701A (OSRAM)
PL (2) PL2620451T3 (OSRAM)
PT (2) PT2620451T (OSRAM)
RS (2) RS55447B1 (OSRAM)
SI (2) SI2137217T1 (OSRAM)
WO (1) WO2008124570A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241235B2 (en) 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
MX2009010701A (es) 2007-04-05 2010-01-20 Morphotek Inc Metodos para inhibir la union de endosialina a ligandos.
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
US20130305396A1 (en) 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
CA2868989C (en) 2012-03-30 2021-12-14 Morphotek, Inc. Tem-1 diagnostic antibodies
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
EP2964764A1 (en) 2013-03-09 2016-01-13 Baylor College Of Medicine Vascular-targeted t-cell therapy
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3966320A4 (en) 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391302B1 (en) * 1994-03-08 2002-05-21 Ludwig Institute For Cancer Research Method for treating cancers which present antigen FB5 with humanized antibodies

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
EP0686260B1 (en) * 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6263223B1 (en) 1998-09-09 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Method for monitoring arterial oxygen saturation
WO2001068911A2 (en) * 2000-03-15 2001-09-20 Epigenomics Ag Diagnosis of diseases associated with the cell cycle
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
CA2434926C (en) 2001-01-15 2014-04-01 Morphotek, Inc. Chemical inhibitors of mismatch repair
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) * 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
AU2004217442A1 (en) 2003-03-04 2004-09-16 Genzyme Corporation Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
EP1793868B1 (en) * 2004-09-23 2010-12-29 Guerbet Liposomal contrast agents for cest imaging
EP1819736B1 (en) * 2004-12-03 2010-08-04 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
EP2011885B1 (en) * 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
CN101336300A (zh) * 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2041307A2 (en) * 2006-07-13 2009-04-01 Siemens Healthcare Diagnostics GmbH Prediction of breast cancer response to taxane-based chemotherapy
EP2049713A4 (en) * 2006-07-21 2010-06-16 Univ Alberta tissue rejection
EP2069535B1 (en) 2006-08-11 2013-04-10 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
MX2009010701A (es) * 2007-04-05 2010-01-20 Morphotek Inc Metodos para inhibir la union de endosialina a ligandos.
US9186405B2 (en) 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2936256T3 (es) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
US20110117551A1 (en) 2008-02-19 2011-05-19 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010045714A1 (en) 2008-10-20 2010-04-29 University Health Network Methods and compositions for the detection of ovarian cancer
EP2667194A3 (en) 2009-01-14 2014-06-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Ratio based biomarkers and methods of use thereof
WO2010118203A2 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391302B1 (en) * 1994-03-08 2002-05-21 Ludwig Institute For Cancer Research Method for treating cancers which present antigen FB5 with humanized antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Immun., Vol. 6, No. 10 (2006.07.31.) *
Cancer Immun., Vol. 6, No. 10 (2006.07.31.)*

Also Published As

Publication number Publication date
JP5825784B2 (ja) 2015-12-02
DK2137217T3 (en) 2014-03-17
MX2009010701A (es) 2010-01-20
CY1118592T1 (el) 2017-07-12
US20150079104A1 (en) 2015-03-19
HRP20161715T1 (hr) 2017-02-10
PT2620451T (pt) 2016-12-20
EP2620451B1 (en) 2016-09-14
BRPI0809665B8 (pt) 2021-05-25
AU2008237296B2 (en) 2013-07-04
EP2137217B1 (en) 2014-03-05
ES2452929T3 (es) 2014-04-03
CN101918446A (zh) 2010-12-15
EP2620451A1 (en) 2013-07-31
RS53362B (sr) 2014-10-31
AU2008237296A1 (en) 2008-10-16
US20110033455A1 (en) 2011-02-10
EP2137217A1 (en) 2009-12-30
SI2137217T1 (sl) 2014-07-31
RS55447B1 (sr) 2017-04-28
SI2620451T1 (sl) 2017-01-31
PT2137217E (pt) 2014-03-20
US20080248034A1 (en) 2008-10-09
HUE031269T2 (en) 2017-06-28
LT2620451T (lt) 2017-01-10
US9505842B2 (en) 2016-11-29
ES2606906T3 (es) 2017-03-28
DK2620451T3 (da) 2017-01-02
BRPI0809665B1 (pt) 2021-03-23
CN101918446B (zh) 2014-06-18
PL2620451T3 (pl) 2017-06-30
BRPI0809665A2 (pt) 2018-12-04
CA2682726C (en) 2017-05-09
CY1115370T1 (el) 2017-01-04
HRP20140266T1 (hr) 2014-04-25
PL2137217T3 (pl) 2014-08-29
US7807382B2 (en) 2010-10-05
WO2008124570A1 (en) 2008-10-16
US10053509B2 (en) 2018-08-21
WO2008124570A8 (en) 2008-11-27
CA2682726A1 (en) 2008-10-16
JP2013150618A (ja) 2013-08-08
JP2010523592A (ja) 2010-07-15
KR20100016221A (ko) 2010-02-12
US20170029509A1 (en) 2017-02-02
US8895000B2 (en) 2014-11-25

Similar Documents

Publication Publication Date Title
KR101529334B1 (ko) 엔도시알린의 리간드에 대한 결합을 억제하는 방법
US12319741B2 (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
JP6087503B2 (ja) ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
CN109793893B (zh) 用于诊断和治疗癌症的vista调节剂
KR20200035291A (ko) 인터류킨-21 뮤테인 및 치료 방법
KR20150023811A (ko) 암의 치료를 위한 lsr 항체 및 그의 용도
JP2012031172A (ja) Ｔ細胞阻害性受容体組成物およびその使用
CN101189264A (zh) M-csf特异性单克隆抗体及其应用
KR20130108430A (ko) 항-노치1 항체
KR20200044899A (ko) 암의 치료 및 진단을 위한 tim-3 길항제
TW200823235A (en) Prophylactic and therapeutic agent for cancers
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
TW202426504A (zh) Lilrb2抗體產品及方法
KR20120078725A (ko) 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
CN101316861A (zh) Il-17a和il-17f拮抗剂以及使用所述拮抗剂的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140926

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150325

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150610

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150610

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180528

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180528

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190530

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230525

Start annual number: 9

End annual number: 9